On Nov 05, major Wall Street analysts update their ratings for $Ceribell (CBLL.US)$, with price targets ranging from $30 to $32.
J.P. Morgan analyst Robbie Marcus initiates coverage with a buy rating, and sets the target price at $32.
BofA Securities analyst Travis Steed initiates coverage with a buy rating, and sets the target price at $32.
TD Cowen analyst Josh Jennings initiates coverage with a buy rating, and sets the target price at $31.
William Blair analyst Margaret Kaczor initiates coverage with a buy rating.
CCORF analyst William Plovanic initiates coverage with a buy rating, and sets the target price at $30.
Furthermore, according to the comprehensive report, the opinions of $Ceribell (CBLL.US)$'s main analysts recently are as follows:
Ceribell has created a unique, easily transportable/disposable hardware and advanced AI-driven software intended for the diagnosis and ongoing monitoring of patients with non-convulsive seizures in a hospital environment. With a recurring revenue model that generates a leading gross margin profile in the MedTech industry of 85%, and visibility into a 30% revenue growth trajectory over the forthcoming five years, there is confidence in the company's potential to realize significant operating leverage and cash flow production over time.
Ceribell's technology addresses the challenges faced by traditional EEG in the acute care environment, providing workflow improvements for physicians and staff, as well as financial advantages for hospitals.
Here are the latest investment ratings and price targets for $Ceribell (CBLL.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$Ceribell (CBLL.US)$的評級，目標價介於30美元至32美元。
摩根大通分析師Robbie Marcus首次給予買入評級，目標價32美元。
美銀證券分析師Travis Steed首次給予買入評級，目標價32美元。
TD Cowen分析師Josh Jennings首次給予買入評級，目標價31美元。
威廉博萊分析師Margaret Kaczor首次給予買入評級。
CCORF分析師William Plovanic首次給予買入評級，目標價30美元。
此外，綜合報道，$Ceribell (CBLL.US)$近期主要分析師觀點如下：
Ceribell已經開發了一種獨特、易於攜帶/一次性使用的硬件和高級人工智能驅動的軟件，旨在用於對醫院環境中非驚厥性癲癇患者進行診斷和持續監測。通過營收模型產生的重複營業收入，在MedTech行業板塊中擁有領先的毛利率達到85％，以及對未來五年內30％營業收入增長軌跡的可見性，公司有信心能夠在時間的推移中實現顯著的運營槓桿和現金流產出。
Ceribell的技術解決了傳統腦電圖在急性護理環境中面臨的挑戰，爲醫生和工作人員提供了工作流程改進，同時也爲醫院提供了財務優勢。
以下爲今日5位分析師對$Ceribell (CBLL.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
